Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.85 |
| ▸ | NQO2 | P16083 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17823301 | 0.99 | MET (0.84) | METNQO2 | |
| SCHEMBL2460209 | 0.92 | MET (0.83) | METNQO2 | |
| Tepotinib SCHEMBL1296895 | 0.92 | MET (1.00) | METNQO2 | |
| Tepotinib SCHEMBL29379106 | 0.92 | MET (1.00) | METNQO2 | |
| SCHEMBL15906515 | 0.92 | MET (0.82) | METNQO2 | |
| Tepotinib SCHEMBL1295616 | 0.92 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL30259391 | 0.92 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL29550043 | 0.92 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL1296467 | 0.92 | MET (0.98) | METNQO2 | |
| SCHEMBL2458256 | 0.91 | MET (0.83) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | claimed |
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8921357-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-8921357-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| EP-2164843-B1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2367815-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010072296-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MET, TYRO3, ERBB2 | MET 1/4885NQO2 600/4885 |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 562/4885 |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 558/4885 |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 558/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.